Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ
Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ
使用下一代 DNA 序列治疗高胆固醇血症的新方法
批准号：
8645955
负责人：
Richard August Shimkets
金额：
$24.21万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
项目状态：
已结题
起止时间：
2014-02-12 至 2014-11-30
关键词：
AffinityAnimalsAntibodiesAntibody AffinityAntibody RepertoireAntibody-Producing CellsAntigensB-LymphocytesBindingBiological AssayBiotechnologyBusinessesCellsCharacteristicsClinicalClinical TrialsDNADNA SequenceDataDiagnosticDrug TargetingEscherichia coliGenerationsGenesGoalsHarvestHepatocyteHumanHybridomasIL6 geneImmune systemInjection of therapeutic agentLabelLegal patentLibrariesLightLow-Density LipoproteinsLymphoid TissueMarketingMethodsMonoclonal AntibodiesMusOvalbuminPharmacologic SubstancePhasePropertyProteinsPublishingRecombinantsSalesServicesSpeedSurfaceSurface Plasmon ResonanceSystemTechnologyTestingTherapeuticTransgenic MiceTransgenic Organismsbasehypercholesterolemiainstrumentmouse modelneutralizing antibodynext generationnovelnovel therapeutic interventionpublic health relevanceresponsescreeninguptake
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging drug target for hypercholesterolemia, known as PCSK9.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Semi-targeted Immuno-Therapeutic Approach for Treatment of Obesity
-
批准号：8521855
-
项目类别：
-
资助金额：$27.59万
-
财政年份：2013
-
负责人：Richard August Shimkets
-
依托单位：
海外基金
